A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2+ breast cancer

Costa R, Zaman S, Sharpe S, Helenowski I, Shaw C, Han H, Soliman H, Czerniecki B

Drug Design, Development and Therapy 2019, 13:309-316

Published Date: 14 January 2019